Nano Precision Medical’s lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ...
Homicide investigator Efremov makes an unforgivable mistake, as a result of which his colleague, friend and mentor dies. The hero himself loses his sight, but seeks to return to service. Blindness ...
LOS ANGELES & EMERYVILLE, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results